Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties by Frik, Malgorzata et al.
Cyclometalated Iminophosphorane Gold(III) and Platinum(II)
Complexes. A Highly Permeable Cationic Platinum(II) Compound
with Promising Anticancer Properties
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ABSTRACT: New organometallic gold(III) and platinum(II) complexes
containing iminophosphorane ligands are described. Most of them are more
cytotoxic to a number of human cancer cell lines than cisplatin. Cationic Pt(II)
derivatives 4 and 5, which differ only in the anion, Hg2Cl6
2− or PF6
−
respectively, display almost identical IC50 values in the sub-micromolar range
(25−335-fold more active than cisplatin on these cell lines). The gold
compounds induced mainly caspase-independent cell death, as previously
reported for related cycloaurated compounds containing IM ligands. Cyclo-
platinated compounds 3, 4, and 5 can also activate alternative caspase-
independent mechanisms of death. However, at short incubation times cell
death seems to be mainly caspase dependent, suggesting that the main
mechanism of cell death for these compounds is apoptosis. Mercury-free
compound 5 does not interact with plasmid (pBR322) DNA or with calf
thymus DNA. Permeability studies of 5 by two different assays, in vitro Caco-2
monolayers and a rat perfusion model, have revealed a high permeability profile for this compound (comparable to that of
metoprolol or caffeine) and an estimated oral fraction absorbed of 100%, which potentially makes it a good candidate for oral
administration.
■ INTRODUCTION
Cisplatin and the follow-on drugs carboplatin (paraplatin) and
oxaliplatin (eloxatin) have been used to treat different cancers
for the past 40 years.1 However, their effectiveness is still
hindered by clinical problems, including acquired or intrinsic
resistance, a limited spectrum of activity, and high toxicity,
leading to side effects.1,2 In the search for more effective and
selective potential anticancer metallodrugs,3 different ap-
proaches have been pursued, including the study of organo-
metallic compounds. Evidence showing that organometallic
compounds of platinum perform better than their non-
organometallic derivatives was reported.4 In general, organo-
metallic compounds are kinetically more inert and lipophilic
than coordination metal complexes, which may offer oppor-
tunities in the design of anticancer metallodrugs with improved
properties. Several reviews on the anticancer activity of
organometallic compounds from a number of different
transition metals have appeared in the past 5 years.5−17
More specifically, gold(III)3,6 and platinum(II)3,4,18−20
organometallic compounds have been studied as potential
anticancer agents. A number of complexes containing the
[Pt(COD)] fragment and different ligands, such as alkyls,
alkynyls, and nucleosides, have been described.21−23 Platinum
COD alkynyl compounds showed high toxicity against HT-29
colon carcinoma and MCF-7 breast adenocarcinoma cell
lines,24,25 while [PtMe(R-COD)L] compounds26 with different
ligands (halides, alkyl, aryl, alkynyl) revealed higher toxicity to
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HeLa cells in comparison to that of cisplatin. In the case of
gold(III), it is well known that pincer ligands containing carbon
and nitrogen stabilize the metal center against reduction to
gold(I) and gold(0) species in physiological media.27 The
anticancer activities of cyclometalated gold(III) and platinum-
(II) compounds with bidentate C,N- or terdentate C,N,N-
pincer ligands have been recently reviewed.27−29 Some
cyclometalated gold(III) complexes28,30,31 based on C,N,N-
and C,N,C-pincer complexes have displayed impressive
anticancer activity in vitro and in vivo by a mode of action
different from that shown by cisplatin. It has been proposed
that, for these complexes, the presence of the σ(M−C) bond
increases the stability of the compounds allowing the
organometallic fragment to reach the cell unaltered. In addition,
it has been postulated that in platinum compounds the
presence of aromatic groups in the cyclometalated ligand
might favor intercalative binding to DNA (π−π stacking), while
the labile positions in the coordination sphere may favor
covalent coordination for DNA as in cisplatin. Very recently, a
luminescent DNA intercalator cyclometalated platinum(II)-
complex, [Pt(C^N^N)(C-NtBu)]ClO4 (HC^N^N = 6-phenyl-
2,2′-bipyridyl) with a potent inhibitory effect in human cancer
cells in vitro and in a xenograft model in mice has been
described.32 The stabilization of the topoisomerase I−DNA
complex with resulting DNA damage by the cyclometalated
compound is suggested to contribute to its anticancer activity.
Multinuclear (SSCs) fluorescent rhomboidal Pt(II) metalla-
cycles have also been reported recently18 showing a potent
tumor growth inhibitory effect on MDA-MB-231 xenograft
models in mice as well as high stability in media and in cancer
cells in vitro.
We have reported that nontoxic iminophosphorane or
iminophosphane (IM) compounds (R3PN-R′, IM) are useful
precursors for the preparation of coordination (N,N-) or
cyclometalated (C,N-) complexes of d8 (Au(III), Pd(II), and
Pt(II)) and d6 (Ru(II)) metals (selected compounds a−g in
Chart 1). These IM metal complexes display high cytotoxicity
in vitro (low micromolar to nanomolar) against a variety of
human cancer cell lines with different degrees of selectiv-
ity.33−39 Organogold(III) complexes containing iminophos-
phorane ligands (e.g., a) exert cell death with pathways
involving mitochondrial production of reactive oxygen
species.33,34 We have studied the interaction of the IM metal
compounds with (pBR322) DNA, calf thymus (CT) DNA, and
human serum albumin (HSA).33,35−39 We have confirmed that
some compounds (such as f) inhibit PARP-1 proteins.37 More
recently,39 we have described a water-soluble ruthenium(II) IM
compound (g in Chart 1) which has displayed high activity
against a number of cancer cell lines in vitro. This compound
was also highly active on MDA-MB-231 xenografts in mice,
with an impressive tumor reduction (shrinkage) of 56% after 28
days of treatment (14 doses of 5 mg/kg every other day), with
low systemic toxicity, quick absorption in plasma, and
preferential accumulation in breast tumor tissues.39 In most
cases (including some Pd(II) and Pt(II) derivatives), we have
demonstrated that DNA is not the target for these compounds
and that most complexes are highly active against cisplatin-
resistant cancer cell lines, pointing to a mode of action different
from that of cisplatin.34−39 We also evaluated the stability of the
compounds in solution and proved that, for gold(III) and
palladium(II) metal centers, cyclometalated C,N-IM com-
pounds were more stable than those in which the IM ligand
was N,N-coordinated.35−38
In this context, we aimed to prepare cyclometalated IM
compounds of gold(III) and platinum(II) in which the aryl
group of the imino fragment is coordinated to the metal center
(exo derivatives such as palladium compounds d and e in Chart
1) as opposed to an aryl group of the phosphine fragment (endo
derivatives like a and b) in order to expand the range of
phosphines incorporated into the final molecule to tune
electronic/steric properties of the resulting complexes. The
synthesis of the exo cyclometalated palladium starting material
containing a water-soluble phosphine (d) was achieved by
oxidative addition of Pd(0) to the C−Br bond in the IM
bromide-containing ligand,36 a method that cannot be used to
generate gold(III) and platinum(II) analogues.
We report here on the synthesis of novel exo cyclometalated
C,N-IM compounds of gold(III) and platinum(II) containing
the water-soluble phosphine 1,3,5-triaza-7-phosphaadamantane
(PTA) and the synthesis of endo-C,N-IM compounds of
platinum(II) derivatives never described before. All these
complexes, along with the previously described exo derivative
Chart 1. Selected Iminophosphorane (IM) d8 and d6 Transition Metal Complexes with Significant Anticancer Properties
Prepared in Our Group33−39
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[Au(2-C6H4C(O)NPPh3)Cl2] (1)40 and cisplatin, have been
evaluated against a number of human cancer cell lines in vitro,
and initial cell death mechanistic insights are discussed. We
have studied the interaction of these compounds with relevant
biomolecules such as plasmid (pBR322) DNA as a model for
nucleic acids and HSA (the most abundant carrier protein in
plasma). The platinum(II) compounds for which effects on
DNA may be expected (3−5) have been further evaluated for
their interaction with CT DNA by circular dichroism (CD). All
these studies point out that cationic cycloplatinated compounds
4 and 5 (differing only in the anion) are the most active and
have a mode of action different from that of cisplatin.
Additionally, we report on the permeability of 4 and 5
evaluated by two different assays, in vitro Caco-2 monolayers
and rat perfusion assay, in order to make comparisons with
cisplatin and drugs or compounds that can be orally
administered.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of the Cyclometalated
Compounds. The synthesis of the exo cyclometalated
gold(III) and platinum(II) compounds was based on the
preparation of [Hg(Ph3PN-CO-2-C6H4)Cl] by Nicholson et
al.40 The C−H activation at the N-CO-Ph fragments takes
place at a manganese center; thus, by transmetalation of the
resulting cyclometalated iminophosphorane manganese com-
pounds to HgCl2, the organomercury derivatives with PPh3,
[Hg(Ph3PN-CO-2-C6H4)Cl],40 or water-soluble phosphine
PTA, [Hg(PTAN-CO-2-C6H4)Cl],37 described by us, are
obtained in high yields (Scheme 1).
Transmetalation reactions of [Hg(PR3N-CO-2-C6H4)Cl]
(PR3 = PPh3;
40 PTA39) with NMe4[AuCl4] or [PtCl2(COD)]
afforded previously described compound [Au(2-C6H4C(O)-
NPPh3)Cl2] (1)40 and new cyclometalated exo-iminophos-
phorane complexes of gold(III) and platinum(II) of the type
[Au(2-C6H4C(O)NPTA)Cl2] (2) and [Pt(2-C6H4C(O)-
NPTA)(COD)]2[Hg4Cl10] (3) (Scheme 2) in moderate to
high yields.
The reaction of [Hg(PPh3N-CO-2-C6H4)Cl] with
[PtCl2(COD)] did not afford a pure cycloplatinated com-
pound. Different synthetic conditions were tried, and in most
cases abundant Pt(0) decomposition took place, while
unreacted [Hg(PPh3N-CO-2-C6H4)Cl] and PPh3O were
the observed products along with free COD. Longer refluxing
times in polar solvents afforded small amounts (4−10%) of a
possible cyclometalated product along with [Hg(PPh3N-CO-
2-C6H4)Cl] and PPh3O.
New compounds 2 and 3 are obtained as air-stable yellow
and white solids, respectively. Compound 2 is neutral, whereas
the Pt(II) derivative 3 is cationic (2:1 ions), as confirmed by
conductivity measurements (see Experimental Section). Com-
pound 3 is only soluble in solvents such as DMSO or DMF. We
found that the COD ligand in 3 is immediately exchanged by
DMSO molecules in DMSO-d6 solution at RT and that the new
IM-cycloplatinated species did not change in DMSO-d6 over
time (see Supporting Information (SI)). This was surprising
since a COD ligand is not easily replaceable (usually requires
thermal activation). The structures of these compounds have
been proposed on the basis of elemental analysis, NMR and IR
spectroscopy, and mass spectrometry (MS). Both compounds
are soluble in mixtures of 1:99 DMSO:H2O at micromolar
concentrations (relevant for biological studies).
The structure of 2 has been determined by an X-ray analysis,
and it is very similar to that previously reported40 for
compound [Au(2-C6H4C(O)NPPh3)Cl2] (1),40 with very
similar distances and angles. The molecular structure of 2 is
depicted in Figure 1, while selected structural parameters are
collected in Table 1.
The analysis confirms the square-planar arrangement around
the gold(III) center with a bite angle of 81.68(8)°. Like in other
Scheme 1. Previously Described Synthesis of Organomercury Compounds Containing the Semi-stabilized IM Ligand PR3N-
CO-2-C6H4
39,40
Scheme 2. Synthesis of Gold(III) and Platinum(II) Cyclometalated exo-Iminophosphorane Complexesa
aCompound [Au(2-C6H4C(O)NPPh3)Cl2] (1) was previously reported.40
Figure 1. Molecular structure of compound 2.
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C,N-IM cycloaurated complexes,33,40−42 the Au−Cl(1) bond
trans to the carbon is longer (2.3834(5) Å) than the Au−Cl(2)
bond trans to the nitrogen (2.2798(5) Å) due to the higher
trans influence of the C donor atom. As observed in compound
1, upon coordination to the gold there is an increase in both the
P−N and N−C bond lengths when compared to the
uncoordinated ligand43 (P−N: 1.626(3) Å in ligand, 1.6658
(18) Å in 2; N−C: 1.353(5) Å in ligand, 1.401(3) Å in 2). This
effect is also observed in the IR spectra of compound 2, for
which the band corresponding to the P−N bond appears at a
lower frequency than that for the free ligand (1289 cm−1 versus
1374 cm−1). As described in the structure of compound 1, a
decrease of the CO bond length was observed (from
1.245(5) Å in the ligand to 1.213(3) Å in the cycloaurated
complex).
We had described the biological activity of the endo-
iminophosphorane compound [Au{κ2-C,N-C6H4(PPh2N-
(C6H5))-2}Cl2]
42 and some of its cationic derivatives, like
[Au{κ2-C,N-C6H4(PPh2N(C6H5)-2}(S2CN(CH3)2)]PF6 (a
in Chart 1),33 but we had never synthesized Pt(II) endo
compounds with the IM Ph-NPPh3 ligand. We carried out
the reaction of [Hg{C6H4(PPh2N(C6H5))-2}Cl]41,42 with
[PtCl2(COD)] and obtained (as in the case of the exo
compound 3) a cationic species (4) with a mercury chloride-
containing anion (in this case [Hg2Cl6]
2−). In order to avoid
the use of organomercury compounds and the presence of
mercury in the resulting compound, a “greener” synthetic
approach44 based on transmetalation with an organogold(I)-
phosphine compound [Au{C6H4(PPh2N(C6H5))-2}-
(PPh3)], described previously,
42 was employed (Scheme 3).
We had used this mercury-free approach to obtain the endo
gold(III) cyclometalated compound [Au{κ2-C,N-C6H4(PPh2
N(C6H5))-2}Cl2].
42 The reaction proceeds much faster and in
much milder conditions than that for the synthesis of 4 (25 min
at RT in CH2Cl2 instead of 5 days in refluxing acetone), and
compound 5 is obtained in moderate yield (58%). In order to
avoid the formation of a neutral platinum(II) dimer with
chloride bridges, [Pt{C6H4(PPh2N(C6H5))-2}Cl]2, observed
while performing this reaction, NH4PF6 was added. In this way,
we obtained compound 5, an analogue of cationic compound 4
with a mercury-free anion (PF6
−). The structures of these
compounds have been confirmed by elemental analysis, NMR
(including 195Pt NMR) and IR spectroscopy, and MS studies.
In this case the compounds do not exchange the COD ligand
by DMSO molecules at RT in DMSO-d6 solution as it
happened for compound 3, which may have some connotations
for the biological activity of the compounds. Compounds 4 and
5 are soluble in mixtures of 1:99 DMSO:H2O solutions at
micromolar concentrations (relevant for biological studies). A
mercury-free analogue of compound 3 could not be obtained,
since the preparation of the appropriate Au(I) transmetalation
agent from the organomanganese compound (Scheme 1) was
not successful.
The number of cycloplatinated iminophosphorane com-
pounds described previously is limited to two examples of endo
neutral derivatives, [Pt(C6H4-2-PPh2N-C(O)-2-NC5H4-κ-
C,N,N)Cl]45 and [Pt{κ3-C,N,N-C6H4(PPh2N-8-C9H6N}-
Cl],38 in which the iminophosphorane fragment acts as a
C,N,N-pincer ligand. In compounds 3−5, the IM ligand is
cyclometalated in either an exo (3) or endo (4, 5) position,
acting as a C,N-pincer ligand. The other two coordination
positions for the Pt(II) center are occupied by the COD ligand.
The molecular structure for compound 4 was determined by X-
ray crystallography, confirming the proposed structure. The
molecular structure of the cation in 4 is depicted in Figure 2,
while selected structural parameters are collected in Table 2. A
complete drawing of the crystal structure of 4, including the
[Hg2Cl6]
2− anion and crystallization molecules, along with a
more complete table of distances and angles are provided in the
SI. The coordination geometry around the platinum atom is
slightly distorted from square-planarity, with the C(1)−Pt(1)−
N(1) angle of 85.31(9)° suggesting a rigid “bite” angle. The
Table 1. Selected Structural Parameters of Complex 2
Obtained from Single-Crystal X-ray Diffraction Studies
(Bond Lengths in Angstroms and Angles in Degrees)
Au(1)−Cl(1) 2.3834(5) N(1)−Au(1)−Cl(2) 173.33(5)
Au(1)−Cl(2) 2.2798(5) N(1)−Au(1)−Cl(1) 97.32(5)
Au(1)−C(1) 2.020(2) Cl(2)−Au(1)−Cl(1) 88.62(2)
Au(1)−N(1) 2.0497(18) P(1)−N(1)−Au(1) 126.07(10)
P(1)−N(1) 1.6658(18) P(1)−N(1)−C(7) 119.25(15)
N(1)−C(7) 1.404(3) N(1)−C(7)−C(6) 112.16(19)
C(7)−O(1) 1.213(3) N(1)−C(7)−O(1) 123.72(19)
C(7)−C(6) 1.478(3) C(7)−N(1)−Au(1) 114.68(14)
C(6)−C(1) 1.385(3) C(7)−C(6)−C(1) 118.0(2)
C(6)−C(1)−Au(1) 113.24(16)
C(1)−Au(1)−N(1) 81.68(8) N(1)−P(1)−C(10) 113.99(10)
C(1)−Au(1)−Cl(2) 92.44(6) N(1)−P(1)−C(8) 116.45(10)
C(1)−Au(1)−Cl(1) 178.28(6) N(1)−P(1)−C(13) 117.81(10)
Scheme 3. Synthesis of the New Platinum(II) Cyclometalated endo-Iminophosphorane Complexes 4 and 5
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X(1)−Pt(1)−N(1) angle also deviates (94.14(9)°). The
distance Pt−N(1) 2.039(2) Å is shorter than those for other
C,N-cyclometalated Pt(II) derivatives, such as dimethylbenzyl-
amine (dmba) compounds (ca. 2.1230−2.1340 Å) (see, e.g.,
refs 19, 46, and 47). The distances Pt−N(1) and Pt−C(1),
both 2.039(2) Å, are almost identical to those found for Au−
N(1) and Au−C(1), both 2.035(4) Å, in [Au{C6H4(PPh2
N(C6H5))-2}(PPh3)].
42 The distances Pt−X(1) and Pt−X(2)
to the centroids of the COD ligand are 2.169(3) and 2.039(3)
Å, respectively, which reflects the higher trans influence of C
versus N (longer Pt−X(1) distance).
The stability of 1 and of the new compounds 2−5 was
evaluated in DMSO-d6 solution by
31P{1H} and 1H NMR
spectroscopy. All the complexes are stable for months in
DMSO-d6 solution (see spectra and stability table in the SI). As
mentioned before, compound 3 exchanges the COD ligand by
DMSO immediately when dissolved in DMSO-d6 (free COD is
clearly visible along with coordinated DMSO). In the case of
compounds 4 and 5, this exchange is extremely slow, and after
1 week the percentage of free un-coordinated COD observed is
around 6% (see SI). Compounds 4 and 5 are stable in mixtures
of 1:99 DMSO:PBS for 24 h, as established by vis−UV
spectroscopy (see SI). The stability of mercury-free compound
5 in acidic media over time was studied by 1H and 31P{1H}
NMR spectroscopy. Due to the lack of solubility of 5 in
mixtures of 1:99 DMSO:PBS in concentrations high enough to
obtain a meaningful 31P{1H} NMR spectrum, these experi-
ments were performed in a 2:1 DMSO-d6/PBS-1X(D2O)
solution at pH 6 (see Experimental Section for details). In these
conditions compound 5 is stable for at least 5 days, as can be
observed by comparison with its 1H and 31P{1H} NMR spectra
in the same deuterated mixture at pH 7.4 (Figures S9−S12 in
the SI).
Biological Activity in Vitro. Anti-proliferative Studies In
Vitro. The anti-proliferative properties of the gold(III) and
platinum(II) complexes 1−5 and ligand COD were assessed by
monitoring their ability to inhibit cell growth using the MTT
assay (see Experimental Section). The cytotoxicity activity of
the compounds was determined in several human cancer cell
lines, i.e., leukemia Jurkat-T, lung A549, prostate DU-145,
pancreas MiaPaca2, and triple-negative breast MDA-MB-231, in
comparison to cisplatin. The results are summarized in Table 3.
The COD ligand is poorly cytotoxic in all tested cell lines (IC50
> 125 μM). The IM ligands are known to be poorly cytotoxic
(IC50 >100−500 μM in different cell lines).35−38
Cyclometalated neutral gold(III) showed cytotoxicity similar
to that of cisplatin, while compound 2 was less cytotoxic for all
the studied cell lines, with the exception of the leukemia Jurkat
cell line. We have found previously that replacement of PPh3 by
PTA in IM-cyclometalated complexes decreases the cytotox-
icity.39 The IC50 value for Jurkat for compound 1 is very similar
to that obtained for the neutral iminophosphorane endo
derivative [Au{κ2-C,N-C6H4(PPh2N(C6H5))-2}Cl2].42 Cati-
onic gold(III) complexes containing IM ligands are more
cytotoxic than neutral derivatives.33,34 The cationic cyclo-
metalated platinum compounds described here, 3 and especially
4 and 5, were considerably more cytotoxic than cisplatin in all
the cell lines studied. 4 and 5 (same cation) display almost
identical IC50 values, with the exception of A549 and MDA-
MB-231, for which compound 4 containing the Hg2Cl6
2− anion
is twice as active than 5. The data indicate that cytotoxicity for
these compounds comes mainly from the cationic platinum
fragment.
In order to assess the compounds’ selectivity for cancerous
cells with respect to normal cell lines, they were also screened
for their anti-proliferative effects on the non-tumorigenic
human embryonic kidney cells HEK293T. In most cases the
cytotoxicity is comparable for the cancerous and HEK293T
Figure 2. Molecular structure of the cation in compound 4. The anion
[Hg2Cl6]
2− is omitted for clarity.
Table 2. Selected Structural Parameters of the Cation in
Complex 4 Obtained from Single-Crystal X-ray Diffraction
Studies (Bond Lengths in Angstroms and Angles in Degrees)
Pt(1)−C(1) 2.039(2) N(1)−Pt(1)−C(1) 85.31(9)
Pt(1)−N(1) 2.039(2) C(1)−Pt(1)−X(1) 178.95(9)
Pt(1)−X(1) 2.169(3) C(1)−Pt(1)−X(2) 94.79(10)
Pt(1)−X(2) 2.039(2) N(1)−Pt(1)−X(1) 94.14(9)
P(1)−N(1) 1.622(2) N(1)−Pt(1)−X(2) 179.01(9)
P(1)−C(2) 1.773(2) X(1)−Pt(1)−X(2) 85.78(10)
P(1)−C(7) 1.797(3) C(19)−N(1)−Pt(1) 125.82(16)
P(1)−C(13) 1.797(3) C(19)−N(1)−P(1) 116.21(16)
N(1)−C(19) 1.444(3) C(19)−N(1)−P(1) 116.21(16)
C(1)−C(2) 1.409(3)
Table 3. IC50 (μM) of Metal Complexes 1−5, Ligand COD, and Cisplatin in Human Cell Linesa
Jurkat A549 DU-145 MiaPaca2 MDA-MB-231 HEK-293T
1 3.4 ± 0.5 85.3 ± 5.9 40 ± 8.1 81.8 ± 2.6 101.8 ± 16 14.6 ± 1.4
2 9.5 ± 0.07 >125 >125 >125 >125 >125
3 2.13 ± 0.24 20.8 ± 1.7 22.5 ± 4.2 7.53 ± 5.0 14.6 ± 3.7 4.0 ± 0.42
4 0.43 ± 0.06 0.85 ± 0.29 0.93 ± 0.43 0.79 ± 0.09 0.39 ± 0.05 1.25 ± 0.25
5 0.53 ± 0.13 2.01 ± 0.89 0.81 ± 0.07 1.03 ± 0.06 0.84 ± 0.29 0.94 ± 0.07
COD >125 >125 >125 >125 >125 >125
cisplatin 10.8 ± 1.2 114.2 ± 9.1 112.5 ± 33 76.5 ± 7.4 131.2 ± 18 69.0 ± 6.7
aAll compounds were dissolved in 1% DMSO and diluted with water before addition to cell culture medium for a 24 h incubation period. Cisplatin
was dissolved in H2O. Data are expressed as mean ± SD (n = 4).
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cells. All compounds are more toxic to leukemia than to
HEK293T cell lines (2−12 times), and compound 4 is more
toxic to all the cell lines than to the HEK293T cell lines. The
toxicity of mercury-free compound 5 to HEK293T is
comparable to that in the human cancer cell lines. As
HEK293T cell lines (immortalized cells) can display a higher
sensitivity to chemicals, we measured the effect of compound 5
on human renal proximal tubular cells (RPTC). RPTCs in
primary culture have been described as an in vitro model to
study nephrotoxicity.39 The IC50 value (XTT assay 24 h; see SI
for details) for 5 in this cell line was 2.77 ± 0.83 μM, making 5
more sensitive to cancerous cell lines than to RPTCs. In
addition, we have described recently an IM ruthenium
compound, [(η6-p-cymene)Ru{(Ph3PN-CO-2-N-C5H4)-κ-
N,O}Cl]Cl, which displayed similar IC50 values in vitro for all
the human cancer cell lines described above and HEK293T but
which was very effective in vivo on MDA-MB-231 xenografts in
NOD.CB17-Prkdc SCID/J mice while having low toxicity.
Mechanism of Cell Death for the New Compounds. The
mechanism of cell death induced by mercury-free cytotoxic
cycloplatinated compound 5 was analyzed in two cell lines of
different origin: A549 lung carcinoma and Jurkat T-cell
leukemia. Phosphatidyl serine exposure, plasma membrane
damage, and nuclear morphology were assessed in both cell
lines after treatment with 5. Caspase implication in the toxicity
of 5 was studied using the general caspase inhibitor z-VAD-fmk.
In A549 cells we found that z-VAD-fmk protected cells from 5
at doses up to 0.5 μM (Figure 3), inhibiting both
phosphatidylserine exposure (annexin V binding) and plasma
membrane permeabilization (7-ADD uptake). As expected,
phosphatidylserine exposure was more dependent on caspase
activity. At higher concentrations 7-AAD staining, but not
annexin V binding, increased, suggesting that cell death was
necrotic.
The apparent decrease in the percentage of annexin V-
positive cells could reflect cell disintegration caused by necrosis.
Consistently, z-VAD-fmk did not inhibit cell death at 1 μM
(Figure 3). When an early event of apoptosis, loss of
mitochondrial transmembrane potential, was analyzed, we
also observed that caspase inhibition by z-VAD-fmk only
partially reduced ΔΨm loss caused by 5 (Figure 4), further
suggesting that compound 5 can induce caspase-dependent and
caspase-independent cell death in A549 cells.
Jurkat cells were more sensitive to 5 than A549 cells, with an
IC50 of 0.6 μM, even though this cell line does not express
functional p53, discarding an essential role of this protein in the
activity of compound 5. In these cells, the percentages of 7-
AAD (Figure 5) and annexin V-positive (data not shown) cells
were the same in every assay. High sensitivity of Jurkat cells was
confirmed in short-term experiments, as we observed that 5 at
0.5 μM induced cell death in almost 100% of the cells even at 6
h. Caspase inhibition by z-VAD-fmk completely avoided cell
death at 6 h. However, longer treatment with 5 induced both
Figure 3. Role of caspases on cell death induced by compound 5 in
A595 cells. Cells were cultured for 24 h in the presence of 5 at the
indicated concentrations, alone (solid lines) or combined with the
general caspase inhibitor z-VAD-fmk (dashed lines). Subsequently,
phosphatidylserine exposure (triangles) and cell membrane permeabi-
lization (squares) were analyzed by flow cytometry after staining with
annexin V-DY634 and 7-AAD, respectively. Results are mean ± SD of
two independent experiments with duplicates.
Figure 4. Caspase implication in mitochondrial effects of compound 5
in A549 cells. Cells were cultured for 24 h in the presence of
compound 5 at the indicated concentrations, alone (solid line) or
combined with the general caspase inhibitor z-VAD-fmk (dashed line).
Then, transmembrane mitochondrial potential was analyzed by flow
cytometry after cells were stained with the probe DiOC6(3). Results
are mean ± SD of two independent experiments with duplicates.
Figure 5. Implication of caspases in cell death induced by compound 5
in Jurkat cells. Cells were treated with compound 5 for 6 or 24 h in the
presence or in the absence of the general caspase inhibitor z-VAD-fmk.
Membrane integrity was analyzed by flow cytometry after the cells
were stained with 7-AAD, as indicated in the Experimental Section.
Results are mean ± SD of two independent experiments.
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caspase-dependent and caspase-independent cell death (Figure
5).
Mitochondrial damage was also analyzed in Jurkat cells
(Figure 6). At 24 h, treatment with 5 caused a decrease in
ΔΨm in 80% of cells, compared to 32% in cells treated with 5
in the presence of the general caspase inhibitor z-VAD-fmk. In
order to determine whether mitochondrial damage caused by 5
was irreversible and committed cells to death, cells were washed
and resuspended in fresh medium. After a further 24 h
incubation in fresh medium, ΔΨm collapse was observed in
nearly 100% of cells (Figure 6). These results indicate that
caspase inhibition only delays cell death in Jurkat cells, and 5
induces cell damage, leading to cell death independently of
caspase activation. Thus, these experiments confirm that
alternative caspase-independent cell death mechanisms are
activated by this compound, as observed in A549 cells.
On the other hand, analysis of nuclear morphology indicated
that 5 induced typical apoptotic features (chromatin con-
densation and fragmentation) that were prevented by z-VAD-
fmk in both cell lines (Figure 7). However, some nuclei of cells
treated with 5+zVAD displayed an altered morphology when
compared to controls. This morphology could be caused by
necroptosis48 or AIF-mediated cell death.49
Finally, we analyzed the implication of mitochondria in the
toxicity of compound 5. We used Jurkat-shBak cells, obtained
by RNAi of Bak.49 Since Jurkat cells do not express Bax, the
Jurkat-shBak cell line constitutes a model of human leukemia
cells deficient in the intrinsic (mitochondrial) pathway of
apoptosis. A cell line transfected with a nonspecific shRNA was
used as a control (Jurkat pLVTHM). As shown in Figure 8,
Jurkat-shBak cells were less sensitive to 5 than control cells.
However, high concentrations of 5 induced Bax/Bak-
independent cell death in Jurkat-shBak cells, suggesting that
this compound could be useful in the treatment of tumors with
alterations in the intrinsic pathway of apoptosis.
We also analyzed the type of cell death for the cycloaurated
exo compounds 1 and 2, the cycloplatinated exo compound 3,
Figure 6. Jurkat cells were treated with 5 or 5+z-VAD for 24 h and
then harvested, washed, and seeded in fresh medium. After further 24
h in fresh medium, mitochondrial transmembrane potential (ΔΨm)
was analyzed as indicated in the Experimental Section. Results are
mean ± SD of three independent experiments.
Figure 7. Compound 5 induces apoptosis in Jurkat (upper panels) and A549 cells (bottom panels). Cells were cultured for 24 h in the presence of
compound 5 (0.5 μM), alone or combined with the general caspase inhibitor z-VAD-fmk or left untreated (Control). Nuclei were stained with
Hoechst 33342 (10 μg/mL), and cells were photographed under UV light. Magnification ×400.
Figure 8. Jurkat-pLVTHM (control) and Jurkat-shBak cells were
treated with compound 5 for 24 h. Mitochondrial transmembrane
potential was analyzed as indicated in the Experimental Section.
Results are mean ± SD of three independent experiments.
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and the cycloplatinated endo compound 4 (analogue of 5
containing the mercury anion Hg2Cl6
2−) in Jurkat cells in the
presence or absence of z-VAD-fmk (caspase inhibitor). This
analysis showed that the gold compounds 1 and 2 were less
toxic than platinum complexes 3 and 4, as already indicated by
the IC50 values (Table 3). Moreover, these results show that
gold compounds 1 and 2 induced mainly caspase-independent
cell death. We had found that iminophosphorane−organogold-
(III) endo compounds also activated caspase-independent
pathways that lead to cell death, as the addition of z-VAD-
fmk did not significantly reduce the percentage of annexin V-
PE+ or PI+ in Jurkat cells treated with these derivatives.34 Thus,
the behavior of iminophosphorane−organogold(III) (both endo
and exo) compounds is basically the same and also similar to
that of other cyclometalated gold(III) anticancer agents.6
The toxicity for the cycloplatinated exo compound 3 (Figure
9) and for the endo compound 4, differing from 5 only in the
anion (data not shown), was only partially dependent on
caspase activity. At 24 h, 3 caused cell death in around 50% of
total Jurkat cells, and caspase inhibition reduced this percentage
to 25%. These data indicate that cycloplatinated compounds 3,
4, and 5 can activate alternative caspase-independent
mechanisms of death. However, at short incubation times,
cell death seems to be mainly caspase dependent (Figure 5),
suggesting that the main mechanism of cell death for these
compounds is apoptosis.
To summarize, from these initial mechanistic studies it seems
clear that the cell death type for the most active mercury-free
cycloplatinated compound 5 is mainly through caspase-
dependent apoptosis but that 5 triggers caspase-independent
cell death when apoptosis is blocked, pointing to a mode of
action different from that of cisplatin.
Lipophilicity and Permeability Assays. The lipophilicity of
the most active cycloplatinated compounds 4 and 5 was
determined by calculating the partition coefficients (see Table 4
and Experimental Section) between n-octanol and phosphate
buffer (pH 7.00). Partition coefficients have been used to
predict the permeability of drugs since there is a good
correlation between intestinal permeability and physicochem-
ical parameters such as lipophilicity. We wanted to study the
influence of the two different anions (Hg2Cl6
2−, 4, and PF6
− in
5) on the lipophilicity and permeability of these cationic
cycloplatinated compounds.
Metoprolol was chosen as the reference compound for
permeability since it is known that 95% of the drug is absorbed
from the gastrointestinal tract. Thus, drugs that exhibit partition
coefficients and human intestinal permeability values greater
than or equal to the corresponding values for metoprolol are
considered high-permeability drugs. Drugs with estimated
partition coefficients and human intestinal permeability values
less than the corresponding values for metoprolol are classified
as low-permeability drugs. This type of correlation is a suitable
source of information on the passive and also possible carrier-
mediated absorption mechanism. From these data we can state
that compound 5 is more lipophilic than 4 and metropolol.
Subsequently, the permeabilities of cisplatin as commercial-
ized parent compound, cycloplatinated 4 and 5 as test
compounds, and metoprolol, cimetidine, and atenolol/Lucifer
Yellow as reference compounds of high, intermediate, and low
permeability, respectively, were determined using an in vitro cell
model based on the measurement of the permeabilities of the
compounds through Caco-2 monolayers50,51 and an in situ
method by performing a rat perfusion assay.52,53 Results from
the in vitro cell assay are shown in Figure 10 and data collected
in Table 5, while the results in the rat model are depicted in
Figure 11 and data collected in Table 6.
PAB is the value corresponding to the permeability from the
apical to the basolateral chamber that simulates the
permeability in the physiological sense from intestine to
plasma. The PBA value corresponds to the permeability from
the basolateral to apical chamber. This PBA value would be the
hypothetical value for the permeability “from plasma to
intestine”. Although the PBA value has no physiological
Figure 9. Jurkat cells were treated with DMSO (Control) or
compound 1 (10 μM), 2 (20 μM), or 3 (10 μM) for 24 h, in the
absence or in the presence of 50 μM z-VAD-fmk. Cell death was
analyzed by annexin V-FITC binding and flow cytometry. Results are
mean ± SD of two independent experiments.
Table 4. Partition Coefficients (Ratio n-Octanol:Phosphate
Buffer) of Compounds 4 and 5 and Reference Metoprolol
compound P log P
metoprolol 0.20 ± 0.02 −0.68
4 0.54 ± 0.03 −0.26
5 1.05 ± 0.05 0.02
Figure 10. Permeability values obtained from apical to basal (PAB)
and from basal to apical (PBA) of cisplatin (at different
concentrations), cycloplatinated 4 and 5, and permeability reference
compounds metoprolol, cimetidine, and Lucifer Yellow at 20 μM in
Caco-2 cells. Data correspond to the averaged values for three
independent experiments.
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sense, this parameter and the ratio PAB/PBA can help to
elucidate the mechanism of drug transport across the intestinal
barrier.54
Cell transport assays reveal that cisplatin is a compound with
very low permeability. This permeability value (5.44 × 10−7cm/
s) indicates that cisplatin is not a suitable drug for oral
administration if the objective is to obtain therapeutic plasma
values. However, organoplatinum compounds 4 and 5 show
higher permeability values than cisplatin. In fact, the
permeability value of compound 4 is 10-fold higher than that
of cisplatin at the same concentration, and the permeability of
compound 5 is 50-fold higher. The permeability of compound
4 is higher than those of Lucifer Yellow and cimetidine but
lower than that of metoprolol. 4 can be considered a compound
of medium oral permeability. However, the permeability of
compound 5 is higher than that of compound 4 and even
higher than that of metoprolol (in accordance with the
lipophilicity data), indicating that it can be considered a highly
permeable compound. The high permeability of active
principles is a crucial condition for oral administration.
Results from the in situ rat model assays confirm those
obtained by the in vitro cell experiments. The permeability of
compound 4 is higher than that of atenolol, slightly higher that
that of cimetidine, but lower than that of metoprolol.
Compound 4 can be considered a compound of intermediate
permeability. Compound 5 exhibits permeability higher than
that of compound 4 and slightly higher than that of metoprolol,
indicating that 5 is a highly permeable compound. Both
compounds 4 and 5 display a much better absorption profile
than cisplatin.
In addition, we have validated the relationship between
Caco-2 cells’ permeability and oral fraction absorbed in our
experimental system (represented in Figure 12) and previously
used for fraction absorbed predictions.54 The permeabilities of
cisplatin and derivatives 4 and 5 have been included in this
correlation. The predicted oral fraction absorbed is more than
60% for compound 4 and almost 100% for compound 5,
demonstrating its improved absorbability properties with
respect to cisplatin. In the absence of solubility or dissolution
limitations the absorption of these compounds would be almost
complete; thus, with the adequate formulation strategy, they
represent promising candidates for oral administration.
3. REACTIVITY WITH BIOMOLECULES
Interactions with DNA. Since DNA replication is the key
event for cell division, it is among the critically important
targets in cancer chemotherapy. Most cytotoxic platinum drugs
form strong covalent bonds with DNA bases.55 However, a
variety of platinum compounds act as DNA intercalators upon
coordination to the appropriate ancillary ligands.56 It has been
reported that most gold(III) compounds display reduced
affinity for DNA,33 although there are a number of Au(III)
porphyrin complexes6,27,57 and cyclometalated species with
C,N,C-pincer ligands6,27,58 that act as DNA intercalators and, in
some cases, as DNA topoisomerase inhibitors. We investigated
Table 5. Permeability Values Obtained by the Caco-2 Cell
Monolayers Assaya
compound (20 μM) Peff (cm/s) SD
cisplatin 5.44 × 10−7 4.66 × 10−7
4 4.62 × 10−6 3.54 × 10−6
5 2.71 × 10−5 5.00 × 10−6
metoprolol 2.32 × 10−5 1.75 × 10−6
cimetidine 1.86 × 10−6 3.71 × 10−7
Lucifer Yellow 1.90 × 10−7 4.98 × 10−8
aMetoprolol, cimetidine, and Lucifer Yellow were used as model
compounds of high, medium, and low oral permeability, respectively.
Data correspond to the averaged values for three independent
experiments.
Figure 11. Absorption rate coefficients in rats.
Table 6. Absorption Rate Coefficients, Ka, and Permeability
Values Obtained from in Situ Rat Assaysa
compound Ka1 (h
−1) SD Peff (cm/s) SD
cisplatinb ND − ND −
4b 2.00 ±0.11 4.72 × 10−5 ±2.60 × 10−6
5b 2.12 ±0.22 5.50 × 10−5 ±5.40 × 10−6
metoprololc 2.30 ±0.15 5.40 × 10−5 ±3.54 × 10−6
cimetidinec 1.68 ±0.12 3.97 × 10−5 ±3.04 × 10−6
atenololc 0.22 ±0.02 5.19 × 10−6 ±4.72 × 10−7
aMetoprolol, cimetidine, and atenolol were used as model compounds
of high, medium, and low oral permeability, respectively. Data
correspond to values of six independent experiments. ND = not
detectable. b20 μM. c100 μM.
Figure 12. Correlation between oral fractions absorbed vs permeability
values obtained from Caco-2 cell monolayers transport assay in apical
to basal direction (PAB). Gray diamonds correspond to the internally
validated correlation (IVC).54 Triangles correspond to permeability
reference compounds (metoprolol/caffeine for high permeability,
cimetidine for intermediate permeability, and Lucifer Yellow for low
permeability). Light gray squares correspond to tested compounds 4
and 5.
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the interactions of the gold(III) and platinum(II) complexes
with plasmid pB322 DNA and with CT DNA and directly
compared them to the same interactions of cisplatin.
Interaction of Complexes 1−5 with Plasmid pBR322
DNA. To gain insight into the nature of the compound−DNA
interactions, gel electrophoresis studies were performed with
gold(III) (1 and 2) and platinum(II) (3−5) complexes on
plasmid (pBR322) DNA (Figure 13). Plasmid pBR322 presents
two main forms, OC (open circular or relaxed) and CCC
(covalently closed or supercoiled), which display different
electrophoretic mobility. Changes in the electrophoretic
mobility of any of the forms upon incubation of the plasmid
with a compound are usually interpreted as evidence of
interaction. Generally, a drug that induces unwinding of the
CCC form will produce a retardation of the electrophoretic
mobility, while coiling of the OC form will result in increased
mobility. Figure 13 shows the effect of cisplatin and compounds
1−5 on plasmid (pBR322) DNA after incubation at 37 °C for
20 h in Tris-HCl buffer at different drug/DNA ratios. As
previously reported, cisplatin is able to both increase and
decrease the mobility of the OC and the CCC forms,
respectively.59 Treatments with increasing amounts of com-
pounds 1, 2, 4, and 5 do not cause any shift for either form,
consistent with no unwinding or other changes in topology
under the chosen conditions. Treatment with increasing
amounts of 3 retards the mobility of the faster-running
supercoiled form (Form I), especially at higher molar ratios.
In order to understand the interaction of 3 with DNA, platinum
compounds 3−5 were incubated with CT DNA and analyzed
by CD.
Interaction with Calf Thymus DNA. More detailed DNA
conformational changes can be detected by means of CD
spectroscopy. CD spectral technique is very sensitive to
diagnose alteration on the secondary structure of DNA that
results from DNA−drug interactions. A typical CD spectrum of
CT DNA shows two conservative bands, a positive band with a
maximum at 273 nm due to base stacking and a negative band
with a minimum at 242 nm due to helipticity, characteristic of
the B conformation of DNA.60 Therefore, changes in the CD
signals can be assigned to corresponding changes in DNA
secondary structures. In addition, it is known that simple grove
binding or electrostatic interaction of small molecules causes
little or no alteration to any of the CD bands when compared
to major perturbation induced by covalent binding or
intercalation. The most dramatic changes in CT DNA can be
observed with compound 3 (Figure 14A). Upon addition of
Figure 13. Electrophoresis mobility shift assays for cisplatin and compounds 1−5 (see Experimental Section for details). DNA refers to untreated
plasmid pBR322. A, B, C, and D correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0, and 2.0, respectively.
Figure 14. CD spectra of CT DNA (195 μM) and CT DNA incubated with 0.1, 0.25, 0.5, and 1.0 equiv of compounds 3 (A), 4 (B), 5 (C), and
cisplatin (D) for 20 h at 37 °C.
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increasing amounts of the complex, the intensity of the positive
band diminishes, and a new negative band at 287 nm and a
positive band at 251 nm appear. This type of modification in
the CD spectrum of CT DNA is characteristic of conforma-
tional changes in DNA from B, the usual right-handed form of
DNA, to Z, the left-handed form of DNA.61 The formation of
left-handed helix of Z-form DNA structure is similar to the
transition seen in purely electrostatic environments such as
those provided by HgCl2
62 and Hg(ClO4)2.
63 Thus, the
presence of [Hg4Cl10]
2− anion in compound 3 seems to lead
to the conformational change from B form to Z form.
Organoplatinum endo compound 4 leads to minor changes of
the B-type CD spectrum (Figure 14B) with slight decrease of
the intensities of the positive bands and with no modification in
the negative region. This points out that the DNA binding of
complex 4 induces conformational changes including con-
version from a more B-like to a more C-like structure within
the DNA molecule.64 This conformational change is indicative
of a non-intercalative mode of binding of the complex and
offers support that the complex is either grove binding or
electrostatic in nature,65,66 and the change might be due to the
lower concentration of Hg2+ released by compound 4,
[Hg2Cl6]
2− (compared to that released by compound 3
containing a [Hg4Cl10]
2− anion), although the influence of
the more lipophilic Pt(II) cation in compound 4, could not be
completely ruled out.
Finally, as shown in Figure 14C, compound 5 does not lead
to any modification of the DNA bands with respect to
untreated CT DNA, suggesting that the interaction of
compound 5 with CT DNA is almost nonexistent. This is in
good agreement with our findings described above about the
influence of the mercury anion in compounds 3 and 4 in their
interaction with CT DNA since the anion in compound 5 is
PF6
−.
In conclusion, the experiments of DNA−drug interactions
have shown that compound 3 induces the formation of left-
handed helix of Z-form DNA through strong electrostatic
interactions and compound 4 appears to be either grove
binding or electrostatic in nature. This is supported by two
main facts: (1) retardation of the plasmid (pBR322) DNA
electrophoretic mobility observed only for compound 3 and (2)
results obtained by CD spectroscopy. Importantly, the
mercury-free cationic organoplatinum compound 5 does not
seem to interact with DNA, indicating that, as for other
transition-metal IM complexes,33−39 its antitumor properties
are due to non-DNA-related mechanisms/factors.
Interactions with Human Serum Albumin. HSA is the
most abundant carrier protein in plasma and is able to bind a
variety of substrates, including metal cations, hormones, and
most therapeutic drugs. It has been demonstrated that the
distribution, the free concentration, and the metabolism of
various drugs can be significantly altered as a result of their
binding to this protein.67 HSA possesses three fluorophores,
namely tryptophan (Trp), tyrosine (Tyr), and phenylalanine
(Phe) residues, with Trp214 being the major contributor to the
intrinsic fluorescence of HSA. This Trp fluorescence is sensitive
to the environment and binding of substrates, as well as
changes in conformation that can result in quenching (either
dynamic or static).
Thus, the fluorescence spectra of HSA in the presence of
increasing amounts of the compounds 1−5 and cisplatin were
recorded in the 300−450 nm range upon excitation of the
tryptophan residue at 295 nm. The compounds caused a
concentration-dependent quenching of fluorescence without
changing the emission maximum or the shape of the peak, as
seen in Figure 15A for compound 3. All these data indicate an
interaction of the compounds with HSA. The fluorescence data
were analyzed by the Stern−Volmer equation (Figure 15B).
Figure 15. (A) Fluorescence titration curve of HSA for compound 3. Arrow indicates the increase of quencher concentration (10−100 mM). Stern−
Volmer plot for HSA fluorescence quenching observed with compounds 1−5 and cisplatin (B), 2−4 and cisplatin (C), and 1, 5, and cisplatin (D).
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While a linear Stern−Volmer plot is indicative of a single
quenching mechanism, either dynamic or static, the positive
deviation observed in the plots of F0/F versus [Q] of
compounds 2−4 (Figure 15C) suggests the presence of
different binding sites in the protein with different binding
affinities.69 Of note, a similar behavior was observed in the case
of coordination iminophosphorane complexes of d8 metals, for
which we also reported a concentration-dependent fluorescence
quenching.35−39 On the other hand, the Stern−Volmer plot for
complexes 1 and 5 shows a linear relationship (Figure 15D),
suggesting the existence of a single quenching mechanism, most
likely dynamic, and a single binding affinity. The Stern−Volmer
constants for complexes 1 and 5 are 4.58 × 106 and 3.67 × 106
M−1, respectively.
In general, higher quenching by the iminophosphorane
complexes was observed compared to that of cisplatin under
the chosen conditions, most likely due to the faster reactivity of
our compounds with HSA, as compared to cisplatin.
■ CONCLUSIONS
We have reported on the synthesis and anticancer properties of
cyclometalated neutral gold(III) and cationic platinum(II)
derivatives containing iminophosphorane ligands. Most com-
pounds are more cytotoxic to a number of human cancer cell
lines than cisplatin. The gold compounds induced mainly
caspase-independent cell death, as previously described for
related cycloaurated iminophosphorane compounds. Cyclo-
platinated compounds 3, 4, and 5 can also activate alternative
caspase-independent mechanisms of death. However, at short
incubation times cell death seems to be mainly caspase
dependent, suggesting that the main mechanism of cell death
for these compounds is apoptosis. The most promising
candidate is the mercury-free lipophilic cationic cycloplatinated
compound 5. This derivative is much more active (25−300-
fold) than cisplatin against a number of cancer cell lines while
being less toxic on human renal proximal tubular cell lines.
These facts, along with the lack of interaction observed for 5
with plasmid (pBR322) and CT DNA, point to a mode of
action different from that of cisplatin. Permeability studies of 5
by two different assays, in vitro Caco-2 monolayers and a rat
perfusion model, have revealed its high permeability profile
(comparable to that of metoprolol or caffeine) and an
estimated oral fraction absorbed of 100%, which potentially
makes it a good candidate for oral administration. The results
described for 5 and those recently reported for a ruthenium−
iminophosphorane compound highly active in vivo against
breast cancer39 warrant further advanced preclinical studies
with selected organometallic iminophosphorane compounds.
The work described in this paper supports the idea that
nontoxic iminophosphorane molecules are excellent ligands for
the synthesis of organometallic compounds of d6 and d8 metals
(especially cationic species) with relevant anticancer properties,
high permeability, and, in some cases, water-solubility.
■ EXPERIMENTAL SECTION
All manipulations involving air-free syntheses were performed using
standard Schlenk-line techniques under a nitrogen atmosphere or in a
glovebox (MBraun MOD system). Solvents were purified by use of a
PureSolv purification unit from Innovative Technology, Inc. The
phosphine substrates TPA and PPh3 were purchased from Sigma-
Aldrich, [Mn2(CO)10] and [PtCl2(COD)] were purchased from Strem
Chemicals, and Na/Hg were purchased from Fisher Scientific and used
without further purification. Compounds [PhCH2Mn(CO)5],
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[Hg(2-C6H4C(O)NPPh3)Cl],40 and [Hg(2-C6H4C(O)NPTA)-
Cl]39 and IM ligands Ph3PN-CO-2-N-C5H469 were prepared by
reported methods. The purity of the compounds, based on elemental
analysis, is ≥99.5%. NMR spectra were recorded on a Bruker AV400
instrument (1H NMR at 400 MHz, 13C NMR at 100.6 MHz, 31P NMR
at 161.9 MHz, 195Pt NMR at 85.7 Hz). Chemical shifts (δ) are given in
ppm using CDCl3 or DMSO-d6 as solvent, unless otherwise stated.
Elemental analyses were performed on a PerkinElmer 2400 CHNS/O
analyzer, Series II. High-resolution electrospray ionization (HR-ESI)
and matrix-assisted laser desorption/ionization (MALDI) mass spectra
were obtained on an Agilent analyzer or a Bruker analyzer.
Conductivity was measured in an Oakton pH/conductivity meter in
acetone solution (10−3 M). X-ray collection was performed at room
temperature (RT) using graphite-monochromated and 0.5 mm
MonoCap-collimated Mo Kα radiation (λ = 0.71073 Å) with the ω
scan method. CD spectra were recorded using a Chirascan CD
spectrometer equipped with a thermostated cuvette holder. Electro-
phoresis experiments were carried out in a Bio-Rad Mini subcell GT
horizontal electrophoresis system connected to a Bio-Rad Power Pac
300 power supply. Photographs of the gels were taken with an Alpha
Innotech FluorChem 8900 camera. Fluorescence intensity measure-
ments were carried out on a PTI QM-4/206 SE spectrofluorometer
(PTI, Birmingham, NJ) with right angle detection of fluorescence
using a 1 cm path length quartz cuvette.
Synthesis. [Au(2-C6H4C(O)NPTA)Cl2] (2). [Hg(2-C6H4C(O)-
NPTA)Cl] (0.15 g, 0.3 mmol), [NMe4][AuCl4] (0.12 g, 0.2
mmol), and [NMe4]Cl (0.035 g, 0.32 mmol) were stirred at RT in
CH2Cl2 (15 mL) for 1 day in a foil-covered flask. The solvent was
removed under reduced pressure. The fraction containing compound
2 was then extracted from the solid residue with CHCl3 (3 × 10 mL),
and the resulting yellow solution was filtered through Celite. The
volume was reduced (<3 mL), and upon addition of Et2O (20 mL) a
pale yellow solid was precipitated. This solid was finally isolated by
filtration and dried in vacuo. Yield: 0.15 g (93%). Anal. Calcd for
C13H16N4OPCl2Au (543.14): C, 28.75; H, 2.97; N, 10.32. Found: C,
28.32; H, 3.07; N, 9.93. ESI-MS: m/z 507.04 (100%, [M−Cl]+, calcd
507.04). 31P{1H} NMR (CDCl3): δ −7.66 (s); (DMSO-d6): δ −2.68
(s). 1H NMR (CDCl3): δ 4.54 (6H, AB system, NCH2N), 5.10 (6H,
d, 2JPH = 9.1 Hz, PCH2N), 7.34 (1H, d,
3JHH = 7.0 Hz, 6-C6H4), 7.38
(dd, 3JHH = 7.8,
3JHH = 7.8 Hz, 4-C6H4), 7.42 (dd,
3JHH = 7.2,
3JHH =
7.1 Hz, 5-C6H4), 8.04 (d,
3JHH = 8.1 Hz, 3-C6H4).
13C{1H} NMR: δ
55.78 (d, 1JPC = 36.8 Hz, PCH2N), 72.37 (d,
3JPC = 10.8 Hz, NCH2N),
128.64 (s, 2-C6H4), 129.73 (s, 3-C6H4), 130.74 (s, 5-C6H4), 134.42 (s,
4-C6H4), 143.16 (s, Au−C) ppm. Signals corresponding to NCO
and C1 not observable. IR (cm−1): ν 352 (Au−Cl), 1299 (NP)
1654 (CO). Conductivity: 37.66 μS/cm (acetone) (neutral).
[Pt(2-C6H4C(O)NPTA)(COD)]2Hg4Cl10 (3). [Hg(2-C6H4C(O)N
PTA)Cl] (0.225 g, 0.44 mmol) and [PtCl2(COD)] (0.165 g, 0.44
mmol) were refluxed in CH3CN (20 mL) for 2 h, affording a white
solid that was filtrated off and washed with Et2O (3 × 10 mL),
benzene (2 × 5 mL), and hexane (2 × 10 mL). After drying in vacuo,
complex 3 was isolated as a white powder. Yield: 0.097 g (40%). Anal.
Calcd for C42H56Cl10Hg4N8O2P2Pt2 (2313.94): C, 21.80; H, 2.44; N,
4.84. Found: C, 21.72; H, 2.58; N, 4.72. ESI-MS: m/z 470.1 ([M−
COD−Hg4Cl10]+, calcd 470.4), 578.2 (100%, [M−Hg4Cl10]+, calcd
577.9), 1275.0 (100%, [2M−Hg4Cl6]2+ + CCl3−, calcd 1275.4).
31P{1H} NMR (CDCl3): δ −7.66 (s); (DMSO-d6): −10.25 (s).
195Pt{1H} NMR (DMSO-d6): δ −3652.87 (s). 1H NMR (DMSO-d6):
δ 2.30 (8H, s, COD), 4.39 (6H, s, NCH2N), 4.91 (6H, d,
2JPH = 10.3
Hz, PCH2N), 5.51 (4H, s, COD), 7.07 (1H, m, 4-C6H4), 7.16 (1H, m,
5-C6H4), 7.29 (1H, d,
3JHH = 7.3 Hz, 6-C6H4), 8.15 (1H, d,
3JHH = 8.0
Hz, 3-C6H4).
13C{1H} NMR (DMSO-d6): δ 27.98 (s, COD), 54.27 (d,
1JPC = 39.2 Hz, PCH2N), 71.30 (d,
3JPC = 10.2 Hz, NCH2N), 124.6 (s,
4-C6H4), 128.1 (s, 6-C6H4), 128.9 (s, COD), 131.9 (s, 5-C6H4), 132.7
(s, 3-C6H4), 135.0 (s, 1-C6H4), 138.0 (d,
2JCPtc = 10.2 Hz, 2-PtC),
182.1 (d, 2JPC = 5.18 Hz, CO) ppm. IR (cm−1): ν 1300 (NP),
1643 (CO). Conductivity: 129 μS/cm (DMF) (1:2 electrolyte).
[Pt{κ2-C,N-C6H4(PPh2N(C6H5)(COD)]2(Hg2Cl6) (4). [Hg-
{C6H4(PPh2N(C6H5)}Cl] (0.18 g, 0.3 mmol) and [PtCl2(COD)]
(0.11 g, 0.3 mmol) were refluxed in acetone (30 mL) for 5 d. The
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solvent was removed under reduced pressure. The final product was
extracted with CH2Cl2 and the resulting solution filtered through
Celite, giving a light yellow solution. The solution was concentrated
(<3 mL), and upon addition of Et2O (20 mL) the final product was
precipitated as a white solid, isolated by filtration, and dried in vacuo.
Yield: 0.20 g (72%). Anal. Calcd for C64H62N2P2Cl6Pt2Hg2·CH2Cl2
(1961.24): C, 38.84; H, 3.21; N, 1.39. Found: C, 38.84; H, 3.42; N,
1.30. ESI-MS: m/z 655.18 (100%, [M]+, calcd 655.18). 31P{1H} NMR
(CDCl3): δ 64.51 (s); (DMSO-d6): δ 63.19 (s).
195Pt{1H} NMR
(CDCl3): δ −3622.47 (d, 2JPPt = 404 Hz). 1H NMR (CDCl3): δ 2.66
(8H, m, COD), 5.12−5.30 (4H, m, COD), 6.88 (2H, m, 2-,6-NAr),
7.12 (1H, m, 4-NAr), 7.21 (2H, m, 3-,5-NAr), 7.35 (1H, m, 4-C6H4),
7.56−7.67 (10H, m, o-,m-,p-C6H5), 7.75 (2H, m, 5-C6H4). 13C{1H}
NMR (CDCl3): δ 28.24 (s, COD), 31.23 (s. COD), 89.30 (s, COD),
116.12 (s, COD), 124.3 (d, 1JPC = 91.6 Hz, Ci), 127.1 (d,
5JPC = 2.7
Hz, 4-NAr), 127.8 (d, 3JPC = 13.9 Hz, 4-C6H4), 129.5 (d,
3JPC = 2.9,
Hz, m-C6H5), 129.7 (s, 3-,5-NAr), 130.1 (d, J = 4.8 Hz, 2-,6-NAr),
132.7 (d, 2JPC = 14.3 Hz, 3-C6H4), 133.3 (m, o-,p-C6H5), 134.3 (d,
4JPC
= 2.3 Hz, 5-C6H4), 147.8 (s, Pt−C). IR (cm−1): ν 529 (Pt−N), 1310
(NP). Conductivity: 102.3 μS/cm (acetone) (1:1 electrolyte).
[Pt{κ2-C,N-C6H4(PPh2N(C6H5)(COD)](PF6) (5). [Au{C6H4(PPh2
N(C6H5))-2}(PPh3)] (0.28 g, 0.3 mmol) and PtCl2(COD) (0.11 g,
0.3 mmol) were stirred in CH2Cl2 (20 mL) for 25 min at RT, follow
by addition of NH4PF6 (0.049 g, 0.3 mmol). The resulting solution
was stirred for an additional 1 h. The solution was concentrated (<3
mL), dry Et2O (20 mL) was added, affording a gray precipitate, and
the solution was stirred for 10 min. The precipitated gray solid was
isolated by filtration and washed with water (4 × 2 mL) and a cold
mixture (1:8) of CH2Cl2/Et2O (4 × 5 mL), yielding a white solid that
was dried in vacuo. Yield: 0.14 g (58%). Anal. Calcd for
C32H31F6NP2Pt (800.63): C, 48.01; H, 3.90; N, 1.75. Found: C,
47.74; H, 4.11; N, 1.74. ESI-MS: m/z 655.18 (100%, [M]+, calcd
655.18). 31P{1H} NMR (CDCl3): δ 64.65 (s); (DMSO-d6): δ 63.19
(s). 195Pt{1H} NMR (CDCl3): δ −3614.48 (d, 2JPPt = 406.1 Hz). 1H
NMR (CDCl3): δ 2.64 (8H, m, COD), 5.20 (4H, m, COD), 6.88 (2H,
m, 2-,6-NAr), 7.09 (1H, m, 4-NAr), 7.20 (2H, m, 3-,5-NAr), 7.23 (1H,
m, 3-C6H4), 7.33 (1H, m, 4-C6H4), 7.49−7.66 (10H, m, o-,m-,p-C6H5),
7.72 (2H, m, 5-C6H4).
13C{1H} NMR (CDCl3): δ 28.05 (s, COD),
31.02 (s, COD), 89.22 (s, COD), 116.49 (s, COD), 124.3 (s, Cipso),
125.2 (s, Cipso), 127.0 (d,
5JPC = 2.9 Hz, 4-NAr), 127.6 (d,
5JPC = 13.9
Hz, 4-C6H4), 129.5 (d,
3JPC = 2.5, Hz, m-C6H5), 129.6 (s, 3-,5-NAr),
130.1 (d, 3JPC = 4.9 Hz, 2-,6-NAr), 132.6 (d,
2JPC = 13.8 Hz, 3-C6H4),
133.3 (m, o-,p-C6H5), 134.2 (d,
4JPC = 2.9 Hz, 5-C6H4), 147.8 (s, Pt−
C). IR (cm−1): ν 566 (Pt−N), 838 (br, PF6−), 1298 (NP).
Conductivity: 106.5 μS/cm (acetone) (1:1 electrolyte). The stability
of 5 in acidic media over time was studied by 1H and 31P{1H} NMR in
a 2:1 DMSO-d6/PBS-1X(D2O) solution at pH 6. The PBS-1X solution
was prepared using D2O as solvent and adjusting the pH to 7.4 by
addition of 0.1 N HCl. The deuterated PBS-1X solution was then used
to prepare a 2:1 DMSO-d6/PBS-1X(D2O) solution for which the pH
was adjusted to 6 by addition of 0.1 N HCl. Complex 5 was then
dissolved in the 2:1 DMSO-d6/PBS-1X(D2O) solution (pH 6).
Compound 5 dissolved completely in this medium, affording a
colorless solution. A 2:1 DMSO-d6/PBS-1X(D2O) solution at pH 7.4
was prepared to run control NMR experiments.
X-ray Crystallography. A gold block-like crystal with the size of
0.10 × 0.18 × 0.18 mm3 was selected for geometry and intensity data
collection with a Bruker SMART APEXII CCD area detector on a D8
goniometer at 100 K. The temperature during the data collection was
controlled with an Oxford Cryosystems Series 700+ instrument.
Preliminary lattice parameters and orientation matrices were obtained
from three sets of frames. Data were collected using graphite-
monochromated and 0.5 mm MonoCap-collimated Mo Kα radiation
(λ = 0.71073 Å) with the ω and φ scan method. Data were processed
with the INTEGRATE program of the APEX2 software for reduction
and cell refinement. Multiscan absorption corrections were applied by
using the SCALE program for the area detector. The structure was
solved by the direct method and refined on F2 (SHELXTL).2 Non-
hydrogen atoms were refined with anisotropic displacement
parameters, and hydrogen atoms were placed in idealized positions
(C−H = 0.95−0.99 Å) and included as riding with Uiso(H) = 1.2 or
1.5 Ueq(non-H).
Cell Culture, Inhibition of Cell Growth, and Cell Death
Analysis. MTT Toxicity Assays. For toxicity assays, cells (5 × 104 for
Jurkat cells and 104 for adherent cell lines) were seeded in flat-bottom
96-well plates (100 μL/well) in complete medium. Adherent cells
were allowed to attach for 24 h prior to addition of cisplatin or tested
compounds. Compounds were added at different concentrations in
triplicate. Cells were incubated with cisplatin or compounds for 24 h,
and then cell proliferation was determined by a modification of the
MTT-reduction method. Briefly, 10 μL/well of MTT (5 mg/mL in
PBS) was added, and plates were incubated for 1−3 h at 37 °C.
Finally, formazan crystal was dissolved by adding 100 μL/well iPrOH
(0.05 M HCl) and gently shaking. The optical density was measured at
570 nm using a 96-well multiscanner autoreader (ELISA).
Cell Death Analysis. Apoptosis/necrosis hallmarks of cells treated
with compound 5 were analyzed by measuring mitochondrial
membrane potential, plasma membrane integrity, and exposure of
phosphatidylserine. Cells were treated with different concentrations
and at different incubation times as indicated in figure legends. In
some experiments the general caspase inhibitor z-VAD-fmk was added
at 50 μM, 1 h before compounds. For mitochondrial membrane
potential determination, cells (2.5 × 105 in 200 μL) after treatment
with 5 were incubated at 37 °C for 15 min in medium containing 5
nM DiOC6(3) (Molecular Probes). Phosphatidylserine exposure was
quantified by labeling cells with annexin V-DY634 (Invitrogen) after
treatment with 5. Annexin V was added at a concentration of 0.5 μg/
mL in Annexin Binding Buffer (ABB), and cells were incubated at
room temperature for 15 min. Plasma membrane integrity was
evaluated by staining with 7-amino-actinomycin D (7-AAD, Inmuno-
step). At the end of the treatment with 5, cells were incubated for 15
min in 200 μL of PBS containing 50 ng/μL 7-AAD. In all cases, cells
were diluted to 1 mL with ABB or phosphate buffered saline (PBS) to
be analyzed by flow cytometry (FACScan, BD Bioscience, Spain).
Permeability Determinations. Cell Culture and Transport
Assays. Caco-2 cells were grown in Dubelcco’s Modified Eagle’s
Medium containing L-glutamine, fetal bovine serum, and penicillin−
streptomycin. To obtain cells, monolayers of 250 000 cells/cm2 were
seeded on each well with polycarbonate membrane with 4.2 cm2 area.
Plates were incubated at standard conditions of 37 °C temperature,
90% humidity, and 5% CO2 until confluence. After 19−21 days, the
integrity of the each cell monolayer was evaluated by measuring the
trans-epithelial electrical resistance (TEER). Values ranging 500−750
Ω·cm2 were considered appropriate.
Transport studies were performed using an orbital environmental
shaker at constant temperature (37 °C) and agitation rate (50 rpm).
Hank’s balanced salt solution (HBSS) supplemented with HEPES was
used to fill the receiver chamber and to prepare the drug solution
placed in the donor chamber. Four samples of 200 μL each were taken
from the receiver chamber side at predefined times (15, 30, 60, and 90
min) and replaced with the same volume of fresh buffer. Moreover,
two samples of the donor side were taken at the beginning and the end
of the experiment. The amount of compound in cell membranes and
inside the cells was determined at the end of the experiments in order
to check the mass balance, and the percentage of compound retained
in the cell compartment was always less than 5%.
Transport studies were performed in both directions, from apical-
to-basal (A-to-B) and from basal-to-apical (B-to-A) sides. The volume
of donor compartment was 2 mL in A-to-B direction and 3 mL in B-
to-A direction.
Analysis of the Samples. Samples were analyzed by HPLC using a
5 μm, 4 × 200 mm Novapack C18 column. Samples of cisplatin and
compound 4 were analyzed with UV detection (λ = 240 nm). The
mobile phase was 95:5 acetonitrile:water, with a flow rate of 1 mL/
min, and the injected sample volume was 50 μL. Samples of
compound 5 were analyzed similarly but using a UV detector at λ =
215 nm and a mobile phase of 80:20 acetonitrile:water.
Data Analysis. The apparent permeability coefficient was calculated
following the equation
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where Creceiver,t is concentration of compound in the receiver chamber
at time t, Qtotal is the total amount of drug in both chambers, Vreceiver
and Vdonor are the volumes corresponding to receiver and donor
compartment, respectively, in each chamber, Creceiver,t−1 is the
concentration of compound in the receiver chamber at the previous
time, f is the sample dilution factor due to replaced volume, S is the
surface area of the monolayer, Δt is the time interval, and P is the
permeability coefficient. This equation takes into account the
continuous change of the donor and receiver concentrations, i.e.,
non-sink conditions. However, when the transport rate is low, there
are not significant changes between the donor and the receiver
concentrations with time. Sink conditions are assumed, and a simpler
expression can be used to estimate the permeability coefficient:
=P Q t
CS
d /d
(2)
where dQ/dt is the apparent appearance rate of drug in the receiver
side calculated using linear regression of amounts in the receiver
chamber versus time, S is the surface area of the monolayer, and C is
the drug concentration in the donor chamber.
The permeability coefficient estimations in sink and non-sink
conditions were carried out in an Excel worksheet. Studies were
performed in triplicate, and the data are presented as mean ± SD.
Student’s t test was performed with SPSS 16.0 (SPSS Inc.) in order to
determine statistically significant differences between A-to-B and B-to-
A permeabilities.
In Situ Absorption Experiments. The absorption experiments were
performed using a Doluisio in situ loop technique.52 The study was
approved by the Scientific Committee of the Faculty of Pharmacy and
followed the guidelines described in the EC Directive 86/609, the
Council of the Europe Convention ETS 123, and Spanish national
laws governing the use of animals in research (Real Decreto 223/1988,
BOE 67, 18-3-98: 8509-8511). Male Wistar rats weighing 280−320 g
were used after 8 h of fasting. Previously to surgical procedure, animals
were anesthetized with diazepam (Valium, Roche) (1.67 mg/kg),
ketamine (Ketolar, Parke-Davis) (50 mg/kg), and atropine (atropine
sulfate, Braun) (1 mg/kg). The body temperature was maintained
during the procedure by heating with a lamp. Therefore, a midline
abdominal incision were performed, and a loop was isolated from the
duodenal and ileal region of each rat. The proximal ligatures of the
duodenal and ileal regions were placed approximately 1 cm from the
pylorus and 2 cm above the ileocecal junction. The bile duct was tight
up in all experiments. First, 50 mL of cleaning solution (Solution A
(pH 7.4): 9.2 g of NaCl, 0.34 g of KCl, 0.19 g of CaCl2·H2O, and 0.76
g of NaH2PO4·2 H2O per liter) was used to flushed out the content of
the loop, and then 20 mL of solution B (NaCl g, NaH2PO4·2H2O 1/
15 M 3.9 mL, Na2HPO4 1/15 M 6.1 mL, and water up to 1 L) was
perfused to condition the intestinal mucosa prior to the experiments. A
catheter was tight up at both intestinal ends and connected to a glass
syringe by the use of a stopcock type valve. Under this setup, the
intestinal segment is an isolated compartment, and the drug solution
can be perfused. The drug solutions were prepared freshly each day at
20 μM using solution B as solvent and perfused into the loop, and
then the entire intestine was restored into the abdominal cavity.
Samples of the perfusate were taken every 5 min for 30 min.
Permeability Calculations. The apparent first-order absorption rate
coefficients (kapp) were obtained by nonlinear fitting of a
monoexponential equation to the luminal concentrations versus time:
= −C C e k t0 app (3)
where C is the drug concentration remaining in the lumen, kapp is the
apparent absorption rate constant, and C0 corresponds to a calculated
fraction of the initial perfusion concentration. Test solutions suffer a
slight dilution in the intestinal lumen due to the remaining cleaning
solution, the adsorption to the membrane, and the loading process in
the enterocyte. So, the intercept, C0, is lower than the perfusion
concentration. The quasi-steady-state is achieved in the membrane
when this process is finished. Under these conditions, the
disappearance of the compound from the lumen can be considered
as a first-order process during the sampling time interval. For these
reasons, only the concentrations obtained after 5 min were used for
regression analysis. In order to obtain good prediction data, water re-
absorption correction was introduced for the concentration calcu-
lations.
The intestinal permeability values were calculated taking into
account the relationship between ka and Peff:
=P k R( )/2eff a (4)
where R is the radius of the intestinal segment, calculated as area/
volume ratio. The effective intestinal permeabilities (Peff) of the tested
compounds (means of at least of three animals) were used as indexes
of the absorption effectiveness.
Interaction of Compounds 1−5 and Cisplatin with Plasmid
(pBR322) DNA by Electrophoresis (Mobility Shift Assay). First,
10 μL aliquots of pBR322 plasmid DNA (20 μg/mL) in buffer (5 mM
Tris-HCl, 50 mM NaClO4, pH 7.39) were incubated with different
concentrations of the compounds 1−5 (in the range 0.25−2.0 metal
complex:DNAbp) at 37 °C for 20 h in the dark. Samples of free DNA
and cisplatin−DNA were prepared as controls. After the incubation
period, the samples were loaded onto 1% agarose gel. The samples
were separated by electrophoresis for 1.5 h at 80 V in Tris-acetate/
EDTA buffer (TAE). Afterward, the gel was stained for 30 min with a
solution of GelRed Nucleic Acid stain.
Interaction of Compounds 3−5 and Cisplatin with Calf
Thymus DNA by Circular Dichroism. Stock solutions (5 mM) of
each complex were freshly prepared in water prior to use. The right
volume of those solutions was added to 3 mL samples of an also
freshly prepared solution of CT DNA (195 μM) in Tris-HCl buffer (5
mM Tris-HCl, 50 mM NaClO4, pH 7.39) to achieve molar ratios of
0.1, 0.25, 0.5, and 1.0 drug/DNA. The samples were incubated at 37
°C for a period of 20 h. All CD spectra of DNA and of the DNA−drug
adducts were recorded at 25 °C over a range 220−330 nm and finally
corrected with a blank and noise reduction. The final data are
expressed in molar ellipticity (millidegrees).
Interaction of Compounds 1−5 and Cisplatin with Human
Serum Albumin by Fluorescence Spectroscopy. A solution of
each compound (8 mM) in DMSO was prepared, and 10 aliquots of
2.5 μL were added successively to a solution of HSA (10 μM) in
phosphate buffer (pH 7.4) to achieve final metal complex
concentrations in the range 10−100 μM. The excitation wavelength
was set to 295 nm, and the emission spectra of HSA samples were
recorded at room temperature in the range of 300−450 nm. The
fluorescence intensities of all the metal compounds, the buffer, and the
DMSO are negligible under these conditions. The fluorescence was
measured 240 s after each addition of compound solution. The data
were analyzed using the classical Stern−Volmer equation, F0/F = 1 +
KSV[Q].
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fellowship. We thank Mr. Tomer Madar (Brooklyn College
undergraduate student at the time) for the initial preparation of
compound 4 and Benelita T. Elie (Brooklyn College-Graduate
Center CUNY Ph.D. student) for testing the IC50 of 5 in RPTC
cell lines.
■ ABBREVIATIONS USED
ABB, Annexin Binding Buffer; CD, circular dichroism; COD,
cyclooctadiene; CT, calf thymus; DMSO, dimethyl sulfoxide;
HSA, human serum albumin; HBSS, Hank’s balanced salt
solution; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid; IM, iminophosphorane; ITC, isothermal titration
calorimetry; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide; PARP-1, Poly(ADP-ribose) Polymerase-1;
PBS, phosphate buffered saline; PTA, 1,3,5-triaza-7-phospha-
adamantane; RPTC, renal proximal tubular cells; TAE, Tris-
acetate/EDTA buffer; TEER, trans-epithelial electrical resist-
ance; T-Jurkat, human acute lymphoblastic leukemia cells; T-
Jurkat sh Bak, human acute lymphoblastic leukemia cells which
do not express the Bak gene; XTT, 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
■ REFERENCES
(1) Thayer, A. M. Platinum drugs take their roll. Chem. Eng. News
2010, 88 (26), 24−28.
(2) Kelland, L. The resurgence of platinum-based cancer chemo-
therapy. Nat. Rev. Cancer 2007, 7, 573−584.
(3) Medici, S.; Peana, M.; Nurchi, V. M.; Lachowicz, J. I.; Crisponi,
G.; Zoroddu, M. A. Noble metals in medicine: latests advances. Coord.
Chem. Rev. 2015, 284, 329−350.
(4) Cullinane, C.; Deacon, G. B.; Drago, P. R.; Hambley, T. W.;
Nelson, K. T.; Webster, L. K. Preparation and cell growth inhibitory
activity of [PtR2L2] (R=polyfluorophenyl, L2=diene, cyclohexane-1,2-
diamine (chxn) or cis-(dimethyl sulfoxide)2) and the X-ray crystal
structure of [Pt(C6F5)2(cis-chxn)]. J. Inorg. Biochem. 2002, 89, 293−
301.
(5) Leonidova, A.; Gasser, G. Underestimated potential of organo-
metallic rhenium complexes as anticancer agents. ACS Chem. Biol.
2014, 9, 2180−2193.
(6) Bertrand, B.; Casini, A. A golden future in medicinal inorganic
chemistry: the promise of anticancer gold organometallic compounds.
Dalton Trans. 2014, 43, 4209−4219.
(7) Liu, W.; Gust, R. Metal N-heterocyclic carbene complexes as
potential antitumor metallodrugs. Chem. Soc. Rev. 2013, 42, 755−773.
(8) Oehninger, L.; Rubbiani, R.; Ott, I. N-heterocyclic carbene metal
complexes in medicinal chemistry. Dalton Trans. 2013, 42, 3269−
3284.
(9) Leung, C.-H.; Zhong, H.-J.; Chan, D.S.-H.; Ma, D. L. Bioactive
iridium and rhodium complexes as therapeutic agents. Coord. Chem.
Rev. 2013, 257, 1764−1776.
(10) Noffke, A. L.; Habtemariam, A.; Pizarro, A. M.; Sadler, P. J.
Designing organometallic compounds for catalysis and therapy. Chem.
Commun. 2012, 48, 5219−5246.
(11) Therrien, B. Drug delivery by water-soluble organometallic
cages. Top. Curr. Chem. 2012, 319, 35−55.
(12) Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer
complexes. J. Med. Chem. 2011, 54, 3−25.
(13) Ang, W. H.; Casini, A.; Sava, G.; Dyson, P. J. Organometallic
ruthenium-based antitumor compounds. J. Organomet. Chem. 2011,
696, 989−998.
(14) Metzler-Nolte, N. Biomedical applications of organometal-
peptide conjugates. Top. Organomet. Chem. 2010, 32, 195−217.
(15) Hillard, E. A.; Vessieres, A.; Jaouen, G. Ferrocene functionalized
endocrine modulators as anticancer agents. Top. Organomet. Chem.
2010, 32, 81−117.
(16) Pizarro, A. M.; Habtemarian, A.; Sadler, P. Activation
mechanisms for organometallic anticancer complexes. Top. Organomet.
Chem. 2010, 32, 21−56.
(17) Olszewski, U.; Hamilton, G. Mechanisms of cytotoxicity of
anticancer titanocenes. Anti-cancer Agents Med. Chem. 2010, 10, 302−
311.
(18) Grishagin, I. V.; Pollock, J. B.; Kushal, S.; Cook, T. R.; Stang, P.
T.; Olenyuk, B. Z. In vivo anticacer activity of rhomboidal Pt(II)
metallacycles. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 18448−18453.
(19) Zamora, A.; Perez, S. A.; Rodriguez, V.; Janiak, C.; Yellol, G. S.;
Ruiz, J. On the Dual Antitumor and Anti-angiogenic Activity of
Organoplatinum(II) Complexes. J. Med. Chem. 2015, 58, 1320−1336.
(20) Chen, Z.-F.; Quin, Q.-P.; Quin, J.-L.; Liu, Y.-C.; Huang, K.-B.;
Li, Y.-L.; Meng, T.; Zhang, G.-H.; Peng, Y.; Luo, X.-J.; Liang, H.
Stabilization of G-quadruplex DNA, inhibition of telomerase activity
and tumor cell apoptosis of organoplatinum(II) complexes with
oxoisoaporphine. J. Med. Chem. 2015, DOI: 10.1021/jm40111t.
(21) Butsch, K.; Elmas, S.; Gupta, N. S.; Gust, R.; Heinrich, F.; Klein,
A.; von Mering, Y.; Neugebauer, M.; Ott, I.; Schafer, M.; Scherer, H.;
Schurr, T. Organoplatinum(II) and -palladium(II) complexes of
nucleobases and their derivatives. Organometallics 2009, 28, 3906.
(22) Klein, A.; Schurr, T.; Scherer, H.; Gupta, N. S. Cytosine Binding
in the Novel Organoplatinum(II) Complex [(COD)PtMe(cytosine)]-
(SbF6). Organometallics 2007, 26, 230.
(23) Klein, A.; Luning, A.; Ott, L.; Hamel, L.; Neugebauer, M.;
Butsch, K.; Lingen, V.; Heinrich, F.; Elmas, S. Organometallic
palladium and platinum complexes with strongly donating alkyl
coligands − Synthesis, structures, chemical and cytotoxic properties. J.
Organomet. Chem. 2010, 695, 1898.
(24) Luning, A.; Schur, J.; Hamel, L.; Ott, I.; Klein, A. Strong
Cytotoxicity of Organometallic Platinum Complexes with Alkynyl
Ligands. Organometallics 2013, 32, 3662.
(25) Luning, A.; Neugebauer, M.; Lingen, V.; Krest, A.; Stirnat, K.;
Deacon, G. B.; Drago, P. R.; Ott, I.; Schur, J.; Pantenburg, I.; Meyer,
G.; Klein, A. Platinum Diolefin Complexes-Synthesis, Structures, and
cytotoxicity. Eur. J. Inorg. Chem. 2015, 2015, 226−239.
(26) Enders, M.; Gorling, B.; Braun, A. B.; Seltenreich, J. E.;
Reichenbach, L. F.; Rissanen, K.; Nieger, M.; Luy, B.; Schepers, U.;
Brase, S. Cytotoxicity and NMR studies of platinum complexes with
cyclooctadiene ligands. Organometallics 2014, 33, 4027−4034.
(27) Cutillas, N.; Yellol, G. S.; de Haro, C.; Vicente, C.; Rodriguez,
V.; Ruiz, J. Anticancer cyclometalated complexes of platinum group
metals and gold. Coord. Chem. Rev. 2013, 257, 2784−2797 and
references therein.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00427
J. Med. Chem. 2015, 58, 5825−5841
5839
(28) Omae, I. Applications of five-membered ring products of
cyclometalation reactions as anticancer agents. Coord. Chem. Rev.
2014, 280, 84−95 and references therein.
(29) To, W.-P.; Zou, T.; Sun, R.W.-Y.; Che, C.-M. Light-induced
catalytic and cytotoxic properties of phosphorescent transition metal
compounds with a d8 electronic configuration. Philos. Trans. R. Soc., A
2013, 371 (1995), 20120126/1−20120126/19 and references therein.
(30) Selected example: Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu,
M. A.; Minghetti, G.; Fregona, D.; Fiebig, H.-H.; Messori, L.
Chemistry, antiproliferative properties, tumor selectivity, and molec-
ular mechanisms of novel gold(III) compounds for cancer treatment: a
systematic study. JBIC, J. Biol. Inorg. Chem. 2009, 14, 1139−1149.
(31) Selected example: Sun, R.W.-Y.; Lok, C.-N.; Fong, T.T.-H.; Li,
C.K.-L.; Yang, Z. F.; Zou, T.; Siu, F.-M.; Che, C.-M. A dinuclear
cyclometalated gold(III)−phosphine complex targetingthioredoxin
reductase inhibits hepatocellular carcinoma in vivo. Chem. Sci. 2013,
4, 1979−1988.
(32) Zou, T.; Liu, J.; Lum, C. T.; Ma, C.; Chan, R.C.-T.; Lok, C.-N.;
Kwok, W.-M.; Che, C.-M. Luminescent cyclometalated platinum(II)
complex forms emissive intercalating adducts with double-stranded
DNA and RNA: differential emissions and anticancer activities. Angew.
Chem., Int. Ed. 2014, 53, 10119−10123.
(33) Shaik, N.; Martínez, A.; Augustin, I.; Giovinazzo, H.; Varela-
Ramirez, A.; Aguilera, R.; Sanau,́ M.; Contel, M. Synthesis of
Apoptosis-Inducing Iminophosphorane Organogold(III) Complexes
and Study of Their Interactions with Biomolecular Targets. Inorg.
Chem. 2009, 48, 1577−1587.
(34) Vela, L.; Contel, M.; Palomera, L.; Azaceta, G.; Marzo, I.
Iminophosphorane-organogold(III) complexes induce cell death
through mitochondrial ROS production. J. Inorg. Biochem. 2011,
105, 1306−1313.
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